CervoMed IncNASDAQ:CRVO
- LAST PRICE23.8200
- TODAY'S CHANGE (%)-1.1700 (-4.6819%)
- Bid / Lots10.0000/ 5
- Ask / Lots26.7300/ 1
- Open / Previous Close24.4400 / 24.9900
- Day Range
- 52 Week Range
- Volume31,022
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRVO |
|---|---|---|
| 09:32 ET | 230 | 24.44 |
| 10:28 ET | 100 | 25.04 |
| 10:33 ET | 723 | 24.71 |
| 10:44 ET | 156 | 24.7 |
| 10:55 ET | 200 | 24.7 |
| 11:02 ET | 100 | 25.19 |
| 11:09 ET | 1958 | 25.075 |
| 11:11 ET | 1195 | 25.035 |
| 11:15 ET | 200 | 25 |
| 11:18 ET | 400 | 24.75 |
| 11:22 ET | 100 | 24.73 |
| 11:40 ET | 100 | 25.19 |
| 11:47 ET | 110 | 25.38 |
| 11:54 ET | 900 | 24.7 |
| 12:05 ET | 100 | 25.25 |
| 12:09 ET | 166 | 24.6501 |
| 12:12 ET | 200 | 25 |
| 12:18 ET | 100 | 25 |
| 12:20 ET | 895 | 24.885 |
| 12:23 ET | 100 | 24.95 |
| 12:25 ET | 100 | 24.9 |
| 12:59 ET | 100 | 25.05 |
| 01:01 ET | 100 | 25.025 |
| 01:26 ET | 900 | 24.71 |
| 01:44 ET | 100 | 25.142 |
| 01:50 ET | 100 | 25.075 |
| 01:53 ET | 300 | 25.2142 |
| 02:04 ET | 2180 | 25.5 |
| 02:08 ET | 100 | 25.13 |
| 02:09 ET | 100 | 25.13 |
| 02:11 ET | 200 | 25.06 |
| 02:26 ET | 1611 | 24.7 |
| 02:27 ET | 100 | 24.94 |
| 02:40 ET | 900 | 24.7 |
| 02:54 ET | 500 | 24.7 |
| 02:58 ET | 150 | 25.05 |
| 03:02 ET | 200 | 25.05 |
| 03:16 ET | 100 | 25.05 |
| 03:20 ET | 300 | 24.7 |
| 03:25 ET | 100 | 25.05 |
| 03:38 ET | 100 | 25.015 |
| 03:41 ET | 100 | 24.6 |
| 03:50 ET | 1696 | 24.01 |
| 03:56 ET | 200 | 24.3 |
| 03:57 ET | 593 | 24.2003 |
| 03:59 ET | 1736 | 23.82 |
Apr 8, 2024
DJ CervoMed Is Maintained at Buy by Canaccord Genuity, from 7:48AM ET on Monday Apr 08, 2024 by Dow Jones
7:48AM ET on Monday Apr 08, 2024 by Dow Jones
Apr 2, 2024
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now, from 7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
Apr 1, 2024
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates, from 8:00AM ET on Monday Apr 01, 2024 by Dow Jones
8:00AM ET on Monday Apr 01, 2024 by Dow JonesPress Release: CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates, from 8:00AM ET on Monday Apr 01, 2024 by Dow Jones
8:00AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CervoMed Inc | 207.3M | -37.9x | --- |
Lineage Cell Therapeutics Inc | 214.9M | -9.2x | --- |
Generation Bio Co | 192.8M | -1.5x | --- |
Adverum Biotechnologies Inc | 190.7M | -0.8x | --- |
INmune Bio Inc | 212.0M | -6.8x | --- |
Actinium Pharmaceuticals Inc | 202.0M | -4.0x | --- |
Company Information
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Contact Information
- Headquarters
- 20 Park Plaza, Suite 424BOSTON, MA, United States 02116
- Phone
- 617-744-4400
- Fax
- 434-220-0722
Executives
- Chairman of the Board
- Joshua Boger
- President, Chief Executive Officer, Director
- John Alam
- Chief Financial Officer
- J.William Tanner
- Chief Operating Officer, Director
- Robert Cobuzzi
- Senior Vice President - Clinical Development
- Kelly Blackburn
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $207.3M |
|---|---|
Revenue (TTM) | $7.1M |
Shares Outstanding | 8.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-0.63 |
Book Value | $1.30 |
P/E Ratio | -37.9x |
Price/Sales (TTM) | 29.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -109.35% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
